Lei Cai
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Lei Cai has a total of 123 co-authors. Here are the top co-authors by number of shared publications:
- Tian Yang
Department of Hepatobiliary Surgery, Eastern Hepatobiliary Surgery Hospital, Naval Medical University, Shanghai, China
4 shared publications Xianxing Wang
Chongqing General Hospital, Chongqing University, Chongqing 400044, P. R. China
4 shared publications- Huaizhi Wang
University of Chinese Academy of Sciences (UCAS) Chongqing School, Chongqing Medical University, Chongqing, China
3 shared publications Jiali Yang
Chongqing General Hospital, Chongqing University, Chongqing 400044, P. R. China
3 shared publicationsMing-Da Wang
3 shared publications- Theodoros Michelakos
Department of Surgery, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts
3 shared publications
Latest Publications
- Open Access
- 21 May 2026
- Published by Royal Society of Chemistry (RSC) in RSC Advances
- Vol. 16 (30) , 27560-27578
A layered double hydroxide nanocarrier enables YM155 delivery-induced PANoptosis and immunogenic activation in hepatocellular carcinoma
Hepatocellular carcinoma (HCC) remains a highly lethal malignancy due to its intrinsic resistance to apoptosis and limited response to conventional chemotherapy. This therapeutic bottleneck is closely associated with aberrant cell death regulation and an immunosuppressive tumor microenvironment, which collectively restrict effective tumor eradication. In this study, a layered double hydroxide (LDH)-based YM155 delivery platform (LDH-YM155) is developed to enhance Survivin-targeted therapy while simultaneously reprogramming tumor cell death toward an inflammatory and immunogenic phenotype. LDH-YM155 exhibits favorable physicochemical stability, pH-responsive YM155 release, and efficient cellular internalization, triggering pronounced oxidative stress and mitochondrial membrane depolarization in Hepa1-6 cells. This stress cascade activates PANoptosis characterized by elevated caspase-3, caspase-8 and caspase-1 activity, ASC speck formation, elevated p-MLKL levels, increased Annexin V/PI-positive populations, and upregulated NLRP3 and RIPK3 signaling. In parallel, LDH-YM155 induces immunogenic cell death-associated events, including enhanced calreticulin exposure, extracellular HMGB1 and ATP release, and increased lactate dehydrogenase release, thereby promoting dendritic cell maturation through tumor cell-conditioned media. Transcriptomic profiling further confirms activation of stimulus-responsive and inflammatory signaling pathways consistent with the observed phenotype. In vivo, LDH-YM155 demonstrates improved tumor accumulation and significantly suppresses tumor growth in a Hepa1-6 tumor-bearing mouse model, accompanied by reduced Ki-67 expression and increased TUNEL staining. Importantly, tumor tissue staining validates elevated NLRP3, RIPK3, and CRT signals with reduced HMGB1 retention, supporting the induction of inflammatory and immunogenic tumor cell death in vivo. Further immune profiling revealed enhanced dendritic cell maturation, pro-inflammatory macrophage polarization, and increased cytotoxic CD8+Granzyme B+ T-cell activation within the tumor microenvironment. Collectively, this LDH-based nanotherapeutic strategy enhances YM155 efficacy by coupling Survivin inhibition with PANoptosis activation and ICD-associated immune stimulation, providing a promising platform for hepatocellular carcinoma therapy.
- 21 May 2026
- Published by Royal Society of Chemistry (RSC) in RSC Advances
- Vol. 16 (30) , 27560-27578
Open AccessA layered double hydroxide nanocarrier enables YM155 delivery-induced PANoptosis and immunogenic activation in hepatocellular carcinoma
Hepatocellular carcinoma (HCC) remains a highly lethal malignancy due to its intrinsic resistance to apoptosis and limited response to conventional chemotherapy. This therapeutic bottleneck is closely associated with aberrant cell death regulation and an immunosuppressive tumor microenvironment, which collectively restrict effective tumor eradication. In this study, a layered double hydroxide (LDH)-based YM155 delivery platform (LDH-YM155) is developed to enhance Survivin-targeted therapy while simultaneously reprogramming tumor cell death toward an inflammatory and immunogenic phenotype. LDH-YM155 exhibits favorable physicochemical stability, pH-responsive YM155 release, and efficient cellular internalization, triggering pronounced oxidative stress and mitochondrial membrane depolarization in Hepa1-6 cells. This stress cascade activates PANoptosis characterized by elevated caspase-3, caspase-8 and caspase-1 activity, ASC speck formation, elevated p-MLKL levels, increased Annexin V/PI-positive populations, and upregulated NLRP3 and RIPK3 signaling. In parallel, LDH-YM155 induces immunogenic cell death-associated events, including enhanced calreticulin exposure, extracellular HMGB1 and ATP release, and increased lactate dehydrogenase release, thereby promoting dendritic cell maturation through tumor cell-conditioned media. Transcriptomic profiling further confirms activation of stimulus-responsive and inflammatory signaling pathways consistent with the observed phenotype. In vivo, LDH-YM155 demonstrates improved tumor accumulation and significantly suppresses tumor growth in a Hepa1-6 tumor-bearing mouse model, accompanied by reduced Ki-67 expression and increased TUNEL staining. Importantly, tumor tissue staining validates elevated NLRP3, RIPK3, and CRT signals with reduced HMGB1 retention, supporting the induction of inflammatory and immunogenic tumor cell death in vivo. Further immune profiling revealed enhanced dendritic cell maturation, pro-inflammatory macrophage polarization, and increased cytotoxic CD8+Granzyme B+ T-cell activation within the tumor microenvironment. Collectively, this LDH-based nanotherapeutic strategy enhances YM155 efficacy by coupling Survivin inhibition with PANoptosis activation and ICD-associated immune stimulation, providing a promising platform for hepatocellular carcinoma therapy.
SLC6A14-mediated carnitine transmembrane uptake from PPAR? + cancer-associated fibroblasts promotes recurrence of pancreatic cancer
Background: Postoperative recurrence is a major contributor to the dismal prognosis of patients with pancreatic cancer (PC). Defining the molecular features of PC with recurrence is crucial for the development of effective therapeutic strategies. Objective: This study aims to identify metabolic and intrinsic metabolism of PC associated with early recurrence. Designs: We analysed resected primary tumours from patients with PC with early (E-Rec) and late (L-Rec) recurrence using an integrated multiomics workflow and spatial metabolomics. Multiplex immunofluorescence quantified carnitine shuttle system (CSS) heterogeneity, and functional in vitro assays alongside in vivo models evaluated pharmacological inhibition of carnitine transport in combination with chemotherapy or immunotherapy. Results: Multiomics analysis revealed SLC6A14 was a key CSS-related gene driving early recurrence of PC. Spatial metabolomics showed elevated carnitine levels in cancer-associated fibroblasts (CAFs) from L-Rec and in tumour cells from E-Rec. Mechanistically, cancer cells used carnitine secreted from PPARγ + CAFs via SLC6A14 uptake, activating the AMPK/PPARα/CPT1B signalling cascade to enhance fatty acid β-oxidation. In vivo experiments demonstrated that pharmacological inhibition of carnitine transport by meldonium, tetrahydropalmatine or quinidine suppressed tumour growth and sensitised tumours to chemotherapy and immunotherapy. Conclusions: PC cells exploit carnitine secreted by PPARγ + CAFs via SLC6A14-mediated uptake to promote tumour recurrence. Targeting the CSS, particularly in combination with chemotherapy or immunotherapy, represents a promising avenue for mitigating recurrence in PC.
SLC6A14-mediated carnitine transmembrane uptake from PPAR? + cancer-associated fibroblasts promotes recurrence of pancreatic cancer
Background: Postoperative recurrence is a major contributor to the dismal prognosis of patients with pancreatic cancer (PC). Defining the molecular features of PC with recurrence is crucial for the development of effective therapeutic strategies. Objective: This study aims to identify metabolic and intrinsic metabolism of PC associated with early recurrence. Designs: We analysed resected primary tumours from patients with PC with early (E-Rec) and late (L-Rec) recurrence using an integrated multiomics workflow and spatial metabolomics. Multiplex immunofluorescence quantified carnitine shuttle system (CSS) heterogeneity, and functional in vitro assays alongside in vivo models evaluated pharmacological inhibition of carnitine transport in combination with chemotherapy or immunotherapy. Results: Multiomics analysis revealed SLC6A14 was a key CSS-related gene driving early recurrence of PC. Spatial metabolomics showed elevated carnitine levels in cancer-associated fibroblasts (CAFs) from L-Rec and in tumour cells from E-Rec. Mechanistically, cancer cells used carnitine secreted from PPARγ + CAFs via SLC6A14 uptake, activating the AMPK/PPARα/CPT1B signalling cascade to enhance fatty acid β-oxidation. In vivo experiments demonstrated that pharmacological inhibition of carnitine transport by meldonium, tetrahydropalmatine or quinidine suppressed tumour growth and sensitised tumours to chemotherapy and immunotherapy. Conclusions: PC cells exploit carnitine secreted by PPARγ + CAFs via SLC6A14-mediated uptake to promote tumour recurrence. Targeting the CSS, particularly in combination with chemotherapy or immunotherapy, represents a promising avenue for mitigating recurrence in PC.
- Open Access
- 11 November 2025
- Published by Springer Nature in Molecular Cancer
- Vol. 24 (1) , 1-22
A novel protein cPFKFB4 encoded by hsa_circ_0065394 strengthens PKM2-mediated glucose metabolic reprogramming to facilitate pancreatic cancer progression under hypoxia
Hypoxia is a hallmark of solid tumors and gives rise to the glucose metabolic reprogramming of cancers. Peptides and proteins encoded by circular RNAs (circRNAs) are identified as pivotal mediators in the malignant progression of tumors. Nonetheless, proteins encoded by hypoxia-related circRNAs in pancreatic cancer (PC) remain uncharacterized and poorly understood. Hypoxia-responsive circRNA (hsa_circ_0065394) in PC was screened using a hypoxic culture system. The circularization mechanism of hsa_circ_0065394 was investigated by employing bioinformatics and RNA immunoprecipitation. An assessment of the expression profile and potential clinical significance of hsa_circ_0065394 in PC was conducted utilizing qRT-PCR and in situ hybridization. Dual-luciferase reporter gene assay, mass spectrometry and western blotting identified a protein cPFKFB4 encoded by hsa_circ_0065394. The biological functions of cPFKFB4 were verified by gain- and loss-of-function experiments in vivo and in vitro. From a mechanistic standpoint, how cPFKFB4 modulates the interaction between hnRNP G and hnRNP A1 as well as the regulation of PKM alternative splicing was explored by conducting mass spectrometry, co-immunoprecipitation, immunofluorescence, PKM splicing, RNA immunoprecipitation, western blotting, and rescue experiments. Hypoxia-associated hsa_circ_0065394 was noticeably up-regulated in PC tissues and tightly associated with tumor size. The biological cyclization of hsa_circ_0065394 was mediated by hnRNP L and Alu repeat sequences. Mechanistically, hsa_circ_0065394 encoded a 94 amino acid protein cPFKFB4 through a cap-independent mechanism. cPFKFB4 disrupted the hnRNP G-hnRNP A1 complex through specific binding to hnRNP G, facilitated hnRNP A1-mediated regulation of PKM alternative splicing, thereby heightening the expression of PKM2, and then strengthening glycolysis of PC cells to accelerate the proliferation and metastasis of PC under hypoxic conditions. cPFKFB4, a protein encoded by hypoxia-responsive circular RNA, facilitates the proliferation and metastasis of PC cells under hypoxic conditions by regulating PKM2-mediated glycolysis. Our findings not only offer fresh standpoints and valuable insights into the crosstalk between hypoxia, glucose metabolism reprogramming, and PC, but also provide a potential biomarker and therapeutic target for the treatment of PC.
- 11 November 2025
- Published by Springer Nature in Molecular Cancer
- Vol. 24 (1) , 1-22
Open AccessA novel protein cPFKFB4 encoded by hsa_circ_0065394 strengthens PKM2-mediated glucose metabolic reprogramming to facilitate pancreatic cancer progression under hypoxia
Hypoxia is a hallmark of solid tumors and gives rise to the glucose metabolic reprogramming of cancers. Peptides and proteins encoded by circular RNAs (circRNAs) are identified as pivotal mediators in the malignant progression of tumors. Nonetheless, proteins encoded by hypoxia-related circRNAs in pancreatic cancer (PC) remain uncharacterized and poorly understood. Hypoxia-responsive circRNA (hsa_circ_0065394) in PC was screened using a hypoxic culture system. The circularization mechanism of hsa_circ_0065394 was investigated by employing bioinformatics and RNA immunoprecipitation. An assessment of the expression profile and potential clinical significance of hsa_circ_0065394 in PC was conducted utilizing qRT-PCR and in situ hybridization. Dual-luciferase reporter gene assay, mass spectrometry and western blotting identified a protein cPFKFB4 encoded by hsa_circ_0065394. The biological functions of cPFKFB4 were verified by gain- and loss-of-function experiments in vivo and in vitro. From a mechanistic standpoint, how cPFKFB4 modulates the interaction between hnRNP G and hnRNP A1 as well as the regulation of PKM alternative splicing was explored by conducting mass spectrometry, co-immunoprecipitation, immunofluorescence, PKM splicing, RNA immunoprecipitation, western blotting, and rescue experiments. Hypoxia-associated hsa_circ_0065394 was noticeably up-regulated in PC tissues and tightly associated with tumor size. The biological cyclization of hsa_circ_0065394 was mediated by hnRNP L and Alu repeat sequences. Mechanistically, hsa_circ_0065394 encoded a 94 amino acid protein cPFKFB4 through a cap-independent mechanism. cPFKFB4 disrupted the hnRNP G-hnRNP A1 complex through specific binding to hnRNP G, facilitated hnRNP A1-mediated regulation of PKM alternative splicing, thereby heightening the expression of PKM2, and then strengthening glycolysis of PC cells to accelerate the proliferation and metastasis of PC under hypoxic conditions. cPFKFB4, a protein encoded by hypoxia-responsive circular RNA, facilitates the proliferation and metastasis of PC cells under hypoxic conditions by regulating PKM2-mediated glycolysis. Our findings not only offer fresh standpoints and valuable insights into the crosstalk between hypoxia, glucose metabolism reprogramming, and PC, but also provide a potential biomarker and therapeutic target for the treatment of PC.
- 22 November 2024
- Published by Elsevier in European Journal of Surgical Oncology
- Vol. 51 (2) , 109486
Incidence, risk factors, outcomes, and prediction model of surgical site infection after hepatectomy for hepatocellular carcinoma: A multicenter cohort study
- 22 November 2024
- Published by Elsevier in European Journal of Surgical Oncology
- Vol. 51 (2) , 109486
Incidence, risk factors, outcomes, and prediction model of surgical site infection after hepatectomy for hepatocellular carcinoma: A multicenter cohort study
- Open Access
- 30 November 2023
- Published by Xia & He Publishing in Cancer Screening and Prevention
- Vol. 2 (4) , 229-237
Outcomes of Patients Undergoing Elective Pancreatic Surgery During COVID-19 Pandemic: A Multicenter, Prospective Cohort Study
The coronavirus disease 2019 (COVID-19) pandemic continues to affect global health, and the emergence of new variants has added a layer of uncertainty to medical practice. Although elective surgeries are recommended to be postponed for at least 7 weeks after severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection to be considered safe, the safety and optimal timing for pancreatic surgery after this infection remains unknown.
- 30 November 2023
- Published by Xia & He Publishing in Cancer Screening and Prevention
- Vol. 2 (4) , 229-237
Open AccessOutcomes of Patients Undergoing Elective Pancreatic Surgery During COVID-19 Pandemic: A Multicenter, Prospective Cohort Study
The coronavirus disease 2019 (COVID-19) pandemic continues to affect global health, and the emergence of new variants has added a layer of uncertainty to medical practice. Although elective surgeries are recommended to be postponed for at least 7 weeks after severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection to be considered safe, the safety and optimal timing for pancreatic surgery after this infection remains unknown.
- Open Access
- 30 November 2023
- Published by Xia & He Publishing in Cancer Screening and Prevention
- Vol. 2 (4) , 229-237
Outcomes of Patients Undergoing Elective Pancreatic Surgery During COVID-19 Pandemic: A Multicenter, Prospective Cohort Study
Cancer is a hereditary multifactorial disease, and due to its rising incidence in both young people and adults along with its substantial burden, oncological emphasis has been placed more on preventive efforts. It has been suggested that several food and lifestyle choices contribute to the onset of cancer, presumably via complex metabolic and inflammatory pathways. Diet is one of the crucial variables in determining cancer risk. In addition, as research intensifies, a more distinct link between diet and patients’ molecular alterations is emerging and becoming quantifiable, dispelling the previous conventional wisdom that linked phenotypic changes to dietary variation. Although the evidence is not consistent, appropriate doses of vitamin B12, vitamin D, vitamin C, selenium, folic acid, and antioxidants such as carotenoids have shown a preventive effect in certain types of cancer. However, improper use of dietary supplements in well-nourished people provides no effects or even poses harmful effects to increase the risk of some cancer. Contrarily, other factors like alcohol, obesity, certain fatty acids, and some techniques used for food preparation may increase the risk of cancer. It is now appropriate to make dietary modifications that are consistent with suggestions for preventing cancer incidence with an emphasis on lifestyle improvement including proper management of problems associated with diet, nutrition, smoking, and drinking. However, there is currently a need for more clinical research to demonstrate the safety and effectiveness of using various phytochemicals or plant extracts as dietary supplements to prevent primary stages of cancer.
- 30 November 2023
- Published by Xia & He Publishing in Cancer Screening and Prevention
- Vol. 2 (4) , 229-237
Open AccessOutcomes of Patients Undergoing Elective Pancreatic Surgery During COVID-19 Pandemic: A Multicenter, Prospective Cohort Study
Cancer is a hereditary multifactorial disease, and due to its rising incidence in both young people and adults along with its substantial burden, oncological emphasis has been placed more on preventive efforts. It has been suggested that several food and lifestyle choices contribute to the onset of cancer, presumably via complex metabolic and inflammatory pathways. Diet is one of the crucial variables in determining cancer risk. In addition, as research intensifies, a more distinct link between diet and patients’ molecular alterations is emerging and becoming quantifiable, dispelling the previous conventional wisdom that linked phenotypic changes to dietary variation. Although the evidence is not consistent, appropriate doses of vitamin B12, vitamin D, vitamin C, selenium, folic acid, and antioxidants such as carotenoids have shown a preventive effect in certain types of cancer. However, improper use of dietary supplements in well-nourished people provides no effects or even poses harmful effects to increase the risk of some cancer. Contrarily, other factors like alcohol, obesity, certain fatty acids, and some techniques used for food preparation may increase the risk of cancer. It is now appropriate to make dietary modifications that are consistent with suggestions for preventing cancer incidence with an emphasis on lifestyle improvement including proper management of problems associated with diet, nutrition, smoking, and drinking. However, there is currently a need for more clinical research to demonstrate the safety and effectiveness of using various phytochemicals or plant extracts as dietary supplements to prevent primary stages of cancer.
- Open Access
More precise measurement of irregular splenic volume in cirrhotic patients with portal hypertension